Third Harmonic Bio
THRD
THRD was delisted on the 30th of July, 2025.
18 hedge funds and large institutions have $1.19M invested in Third Harmonic Bio in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 93 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
76.17% less ownership
Funds ownership: 85.77% → 9.6% (-76%)
83% less funds holding
Funds holding: 105 → 18 (-87)
94% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 93
99% less capital invested
Capital invested by funds: $210M → $1.19M (-$209M)
100% less funds holding in top 10
Funds holding in top 10: 4 → 0 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JC
JBF Capital
Aspen,
Colorado
|
+$1.36M |
| 2 |
CF
Cantor Fitzgerald
New York
|
+$469K |
| 3 |
CSC
Caldwell Sutter Capital
Sausalito,
California
|
+$5.43K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$2.9K |
| 5 |
GI
GAMMA Investing
Foster City,
California
|
+$1.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$56.5M |
| 2 |
O
OrbiMed
New York
|
-$31.4M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$16M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$10.4M |
| 5 |
BlackRock
New York
|
-$9.38M |
THRD Hedge Fund Activity: Q3 2025 in Review
18 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Third Harmonic Bio (THRD) for Q3 2025, worth a combined $1.19M — down 99% from $210M a quarter earlier.
Sellers outnumbered buyers: 93 funds closed out of THRD and 6 opened new positions — a net loss of 87 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was JBF Capital, opening a new position worth an estimated $1.36M. The largest seller was Atlas Venture Life Science Advisors, exiting entirely with an estimated $56.5M sold.
- 18 institutional investors held Third Harmonic Bio (THRD) as of Q3 2025, down from 105 in Q2 2025.
- Funds reported $1.19M of Third Harmonic Bio stock for Q3 2025, down 99% quarter-over-quarter.
- 6 funds opened new Third Harmonic Bio positions in Q3 2025 and 93 closed out, a net change of -87 holders.
- The largest Third Harmonic Bio buyer in Q3 2025 was JBF Capital, an estimated $1.36M added.
- The largest Third Harmonic Bio seller in Q3 2025 was Atlas Venture Life Science Advisors, an estimated $56.5M sold.
Based on aggregated 13F filings for Q3 2025.